GSK Plc
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas. The companys wellness products include Panadol and Panadol Cold & Flu for headache, joint pain, fever, and cold symptoms; ENO and Tums that are immediate relief antacids; and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to smoking reduction and cessation. Its oral health products comprise Sensodyne to treat and prevent dental sensitivity and acid erosion; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; and Aquafresh for the prevention of caries, gum disease, and bad breath. The companys nutrition products include Horlicks, a nutritional beverages and food; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, as well as Zovirax and Abreva to treat and prevent the onset of cold sores. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.
Trading 32% above its estimated fair value of $34.50.
Current Price
$50.90
-1.38%GoodMoat Value
$34.50
32.2% overvaluedGSK Plc (GSK) Quality Analysis
GSK Profitability
GSK Growth
GSK Financial Health
GSK Quality & Fundamental Analysis
GSK Plc (GSK) is a Healthcare company in the Drug Manufacturers - General industry, listed on NYSE. This quality analysis page evaluates GSK Plc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
GSK Plc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of 17.77% and a return on equity (ROE) of 34.68%. Return on assets (ROA) stands at 9.53%.
The debt-to-equity ratio is 1.05, with a current ratio of 0.82. Operating margin is 24.28%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether GSK Plc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.